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Abstract.  Transforming growth factors/~1  and/~2 bind 
with high affinity to the core protein of a 250-350-kD 
cell surface proteoglycan. This proteoglycan (formerly 
referred to as the type III TGF-/3 receptor) coexists in 
many cells with the receptor implicated in TGF-/~ sig- 
nal transduction  (type I TGF-/3 receptor), but its func- 
tion is not known. We report here that soluble TGF- 
/3-binding proteoglycans are released by several cell 
types into the culture media,  and can be found in se- 
rum and extracellular matrices.  As has been shown for 
the membrane-bound form, the soluble proteoglycans 
have a heterogeneous core protein of 100-120 kD that 
carries chondroitin  sulfate and/or heparan  sulfate 
glycosaminoglycan chains and a  small amount of 
N-linked carbohydrate.  The membrane-bound form of 
this proteoglycan is hydrophobic and associates with 
liposomes, whereas the soluble forms lack a mem- 
brane anchor and do not associate with liposomes. 
Differences in the electrophoretic migration of the 
soluble and membrane forms of this proteoglycan sug- 
gest additional structural differences in their core pro- 
teins and glycosaminoglycan chains.  These soluble and 
membrane-bound proteoglycans, for which we propose 
the name "betaglycans," might play distinct roles in 
periceUular retention,  delivery, or clearance of acti- 
vated TGF-B. 
T 
t-IE cell-cell communication  events  that  guide mor- 
phogenesis and tissue repair in pluricellular organisms 
are mediated by cell surface receptors.  Some receptors 
bind diffusible factors whereas others bind adhesion  mole- 
cules located on the surface of other cells or in the extracellu- 
lar matrix.  Although  many membrane receptors are glyco- 
proteins,  several receptors have been recently shown to be 
proteoglycans.  These include syndecan (19), CD44/Hermes 
antigen (11, 32), and the invariant chain associated with mu- 
rine class II major histocompatibility  complex (26),  which 
have been implicated,  respectively,  in epithelial  cell adhe- 
sion to extracellular  matrix components,  lymphocyte homing 
to lymph nodes, and antigen  presentation.  The Drosophila 
gene Toll, required to establish dorsoventral  polarity during 
embryogenesis, encodes a predicted integral membrane pro- 
tein  that  has  amino  acid  sequence similarity  to a  human 
fibroblast proteoglycan core protein (13), and the membrane 
precursor for Alzheimer's disease/~-amyloid  protein appears 
to be associated with a heparan  sulfate proteoglycan (29). 
These two putative proteolgycans may also be involved in in- 
tercellular  recognition  or communication. 
An additional member of this group of receptor-like  mole- 
cules is a 250-350-kD integral membrane proteoglycan that 
is expressed by many mammalian  and avian cells, and has 
the unique property of avidly binding  transforming  growth 
factor-/~ (TGF-B) ~ (6,  7,  8,  24,  30).  TGF-B, which is  the 
prototype of a large family of differentiation,  morphogene- 
1. Abbreviation used in this paper: TGF-~, transforming growth factor-beta. 
sis, and growth suppression factors (23, 34), binds to a site 
located in the  100-120-kD  core of this  proteoglycan.  The 
glycosaminoglycan chains, generally consisting of both chon- 
droitin  sulfate and heparan  sulfate (7, 30), are attached  to a 
domain of the core protein distinct from the TGF-/~-binding 
domain, and are not required for either surface expression 
or TGF-/~ binding  activity of this receptor (4).  This TGF-/~ 
binding proteoglycan,  which was formerly referred to as the 
type III TGF-/~ receptor, coexists in most ceils with the TGF- 
/~ receptor types I and II, two TGF-B-binding  glycoproteins 
of 53 and 73 kD, respectively (6). The function of this pro- 
teoglycan  is not known.  It is not detectable in certain  cell 
types that respond normally to TGF-/~ in vitro (25, 27). Se- 
lection of  chemically induced cell mutants resistant to TGF-/3 
action results with high frequency in the isolation  of clones 
that have selectively lost the type I TGF-/3 receptor,  with no 
apparent effect on the expression of the TGF-/~-binding pro- 
teoglycan  (2).  This evidence implicates  the type I TGF-/~ 
receptor as the mediator of TGF-/~ action,  but leaves un- 
resolved the question of the potential role of the other TGF-/~ 
binding  proteins. 
We report here the existence of forms of the TGF-/~-bind- 
ing  proteoglycan that  lack  the  membrane  anchor.  These 
forms are released by many cell lines  and can be found in 
cell culture fluids, serum, and extracellular  matrices.  Based 
on these findings,  we propose the name  "betaglycans"  to 
designate the members of this group of TGF-B-binding  pro- 
teoglycans. These findings provide new clues about possible 
roles for these molecules in the biology of TGF-/3. 
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Source of  Soluble and Membrane-derived  Betaglycan 
The source, culture conditions, and differentiating conditions (where ap- 
plicable) for 3T3-L1, MvlLu, WI-38, and I-,tE9 cells were as previously de- 
scribed (5,  16, 22, 25). CCL-39 and Rat-I  cells were grown in DME sup- 
plemented with  10%  FCS.  Serum-free washes of cell  monolayers and 
conditioning of serum-free medium were done using Waymouth's  medium 
(Gibco Laboratories, Grand Island, NY). Media used as a source of soluble 
betaglycan had typically been conditioned for 3 d by cell monolayers as they 
reached confluency, or by confluent 3T3-LI adipocyte cultures. Immediately 
after collection, the conditioned media were supplemented with 0.2 mM 
PMSE and cleared of loose cells and debris by centrifugation at 2,000 g 
for 15 rain at 4°C, followed by uitracentrifugation (200,000  g for 40 rain 
at  4°C).  Mycoplasma-free FCS  was  from Gibco  Laboratories (lot  No. 
35K3772). 
To obtain cellular matrix extracts and detergent-soluble cell extracts, cell 
monolayers were first incubated for 30 min at 37°C with a Tris- or Hepes- 
buffered (10 mM, pH 7.4) isotonic saline solution. Extracellular matrix ex- 
tracts, prepared by scraping cell cultures into a  solution containing 1 M 
urea, 10 mM EDTA, 1 mM DTT, 0.2 mM PMSE and 10 mM Tris, pH 7.0, 
as previously described (1, 17), were clarified by centrifugation at 150,000 g 
for 45 min at 4°C. Detergent-soluble  cell extracts were obtained by scraping 
untreated or  affinity-labeled cell  monolayers  into  a  solution containing 
0.25 M sucrose, 10 mM Tris,  1 mM EDTA, 0.1 mM PMSE pH 7.0. The 
cell pellet, obtained by centrifugation at 10,000 g for 10 rain, was solubilized 
by incubation for 40 rain at 4°C with a solution containing 1% Triton X-100, 
10 mM Tris,  I mM EDTA, and a mixture of protease inhibitors (22), and 
was then clarified by centrifugation at 10,000 g for 15 min or at 100,000 g 
for 40 min. 
TGF-~ Binding and A~inity Labeling Assays  for 
Soluble Betaglycan 
These assays were based on the ability of betaglycan to bind to DEAE- 
Sepharose under high salt and acidic pH conditions (7).  Samples of condi- 
tioned media, detergent extracts of cells, or extracellular matrix extracts 
were adjusted to contain 0.25 M NaCl and brought to pH 6.0 by addition 
of 50/zl/ml of 1 M bis-Tris, pH 6.0. Serum samples were diluted with 2 
vol of a solution containing 225 mM NaCI, 75 mM BIS-Tris, pH 6.0. These 
samples  were  then  passed through  a  minicolumn  (0.5  ml)  of DEAE- 
Sepharose Fast Flow (Sigma Chemical Co., St. Louis, MO) that had been 
equilibrated with 0.35 M NaCl, 10 mM BIS-Tris, pH 6.0 (plus 0.5% Triton 
X-100 for detergent-soluble extracts). The column was washed with 3 ml 
of this buffer and was thoroughly drained, unpacked, and resuspended in 
I ml of binding buffer (50 mM NaCI,  10 mM MgCI2,  5 mM KCI, 25 mM 
Hepes, pH 7.6) (22) containing 1 mg/ml of BSA and 150 pM 1251-TGF-51 
alone or with unlabeled TGF-/31 or TGF-/~2 prepared from bovine bone (31). 
After incubation for 3.5 h at 4°C with continued mixing, the beads were 
washed five times with cold binding buffer (without albumin). For binding 
assays, the beads were loaded into a minicolumn, drained, and eluted with 
two column volumes of 0.7 M NaCI, 50 mM BIS-Tris, pH 6.0. The radioac- 
tivity in the eluate was then determined in a gamma counter. For afffinity- 
labeling assays, the washed beads were incubated for 15 min at 4°C with 
1  ml of albumin-free binding buffer containing 0.16  mM disuccinimidyl 
suberate (Pierce Chemical Co., Rockford, IL). The cross-linking reaction 
was stopped by addition of 10 #! of 2 M Tris, pH 7.0. The beads were then 
packed into a minicolumn, drained, and eluted with 0.7 M  NaCI. Triton 
X-100 (1%) was present in all the steps in assays of  detergent-solubilized  cell 
extracts. The eluate from the beads was heated with electrophoresis sample 
buffer, run on a 6% polyacrylamide-SDS gel, and subjected to autoradiog- 
raphy with film (X-Omat; Eastman Kodak Co., Rochester, NY) and an in- 
tensifyiag screen (Cronex; Dupont Co., Diagnostic & Bioresearch Systems, 
Wilmington, DE). 
Affinity labeling of cell monolayers with 125I-TGF-/~ was performed as 
previously described (22). Detergent-soluble extracts from cell monolayers 
were prepared in the presence of protease inhibitors as described above. 
Enzymatic Deglycosylations 
Treatment of cell monolayers with chondroitinase ABC and heparitinase 
was performed as previously described (7). Removal of glycosaminoglycan 
chains from cellular or medium proteoglycans affinity-labeled on DEAE- 
Sepharose beads was carded out by diluting the high salt eluates from these 
beads with 3 vol of 50 mM "Iris, pH 6.8, containing 0.1 mg/ml of BSA and 
the cocktail of protease inhibitors mentioned above. This sample was then 
incubated overnight at 37°C with 0.2  U/ml of chondroitinase ABC (ICN 
K & K Laboratories Inc., Plainview, NY) or 2  x  10  -3 IU/ml of heparitinase 
(ICN K & K Laboratories, Inc.). Proteins were precipitated with either 2 vol of 
acetone at -20°C for at least 4 h in preparation for gel electrophoresis, or 
with 10% TCA in preparation for digestion with endoglycosidase F (Boehr- 
inger Mannheim Biochemicals, Indianapolis, IN) as previously described 
(7).  Samples were heated at  100°C  with sample buffer,  and subjected to 
electrophoresis and autoradiography. 
Liposome Formation 
For these experiments, cell monolayers were affinity labeled, solubilized, 
and clarified by ultracentrifugation as described above, with the exception 
that the detergent used was 70 mM of octylglucoside (Boehringer Mann- 
heim Biochemicais). The solubilized material was bound to and eluted from 
DEAE-Sepharose as described above, with 50 mM of octylglucoside pres- 
ent in all buffers. The resulting high salt eluate was diluted with 4 vol of 
a  50-raM octylglucoside solution.  A  high salt eluate containing affinity- 
labeled betaglycan prepared from conditioned medium was also diluted with 
4  vol  of the 50-raM  octylglucoside solution.  These samples were each 
mixed with 0.5 mg of  egg phosphatidylcholine (Type III-E; Sigma Chemical 
Co.) dried in the bottom of a glass test tube together with  1 /~Ci of 3H- 
dipalmitoyl phosphatidylcholine (Dupont Co. Diagnostic and Research Sys- 
tems; New England Nuclear, Boston, MA). Liposomes were formed by di- 
alysis of these samples against 200 vol of 10 mM Na phosphate, pH 7.0, 
150 mM NaCI, and 0.1 mM PMSF for 24 h at 4°C, with a buffer change 
after 12 h. Dialyzed samples were mixed with 3 vol of  60% (wt/wt) sucrose 
solution in 10 mM Tris,  1 mM EDTA, pH 7, and 2 ml of this sample was 
placed in the bottom of a rotor tube (SW50.1 Beckman Instruments, Inc., 
Palo Alto, CA), overlayed with 2 mi of 30% sucrose solution and 1.3 ml 
of 10% sucrose solution made in the same buffer. Where indicated, 1% Tri- 
ton X-100 was added to the three sucrose solutions. The samples were cen- 
trifuged for 22 h at 45,000  rpm at 4°C and fractionated from top to bottom 
into seven 0.75-ml fractions. 20-/~1 aliquots were taken from each fraction 
and 3H radioactivity was quantitated by scintillation counting. The level of 
125I radioactivity in these samples was negligible compared with the level 
of 3H radioactivity and did not interfere with counting. The rest of the frac- 
tion was counted for 125I radioactivity, diluted with water, precipitated with 
acetone, and the precipitate was subjected to electrophoresis and autoradi- 
ography. 
In some experiments, the fractions were incubated with chondroitinase 
and heparitinase before electrophoresis. Samples were diluted with 2.5 vol 
of a solution containing 50 mM Tris, pH 7.0, 1 mg/ml of BSA, and protease 
inhibitors, and processed for enzymatic deglycosylation  as described above. 
Hydrophobic Chromatography 
DEAE-Sepharose eluates containing affinity-labeled samples from cells and 
medium prepared as described for the liposome reconstitution experiments 
were diluted with 0.7 M NaCl and 10 mM Hepes, pH 7.0, to lower the octyl- 
glucoside concentration to 5 raM. These samples were loaded on a 3-ml 
column of octyI-Sepharose CL-4B (Pharmacia Fine Chemicals, Piseataway, 
NJ) equilibrated with 0.7 M NaCI,  10 mM Hepes, and 5 mM octylgluco- 
side, pH 7.0. The column was washed with this buffer and then eluted with 
a linear gradient of octylglucoside. The 125I radioactivity in the resulting 
fractions was determined by gamma counting. The fractions were then ace- 
tone precipitated and subjected to electrophoresis and autoradiography. 
Results 
Soluble Forms of  Betaglycan 
To  examine whether cells  release  proteoglycans into the 
medium that bind TGF-/3, clarified samples of medium con- 
ditioned by various cell lines were chromatographed over 
DEAE-Sepharose under conditions of high salt and low pH. 
Under these conditions, most of the material that binds to 
DEAE should be strongly anionic and should include any 
sulfated proteoglycans present in the sample. Material bound 
to DEAE-Sepharose was affinity labeled with  '2SI-TGF-/~I 
using disucciminidyl suberate as  the cross-linking agent. 
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dia from various cell lines. Highly anionic material from 12-ml ali- 
quots of media conditioned by the indicated cell lines was bound 
to DEAE-Sepharose in the presence of 0.35 M NaCI, and was 
affinity  labeled with t25I-TGF-~I alone (-) or in the presence of 15 
nM TGF-fll (+). The affinity-labeled  material was eluted from the 
Sepharose beads and displayed by electrophoresis and autoradiog- 
raphy. 
The affinity-labeled  material was eluted with 0.7 M NaCI and 
visualized by electrophoresis and autoradiography. When the 
conditioned media from 3T3-L1 mouse preadipocytic fibro- 
blasts,  differentiated 3T3-LI  adipocytes, CCL-39 Chinese 
hamster lung fibroblasts, and Rat-1 rat embryo fibroblasts 
were assayed in this manner,  strongly labeled species that 
migrated in denaturing electrophoresis gels as broad bands 
of high (>200 kD) molecular mass were detected (Fig.  1). 
The affinity-labeled material from 3T3-L1  cells frequently 
resolved into two broad bands of 200-300 kD and ,x,400 kD, 
respectively (see also Figs. 2, 4, and 6).  Labeling of these 
species was specific and reflected high affinity binding as de- 
termined by inhibition of labeling with the presence of a 
moderate excess (15  nM) of unlabeled TGF-/31 (Fig.  1) or 
TGF-/32 (not shown) during the incubation with 125I-TGF- 
/31. lower but significant levels of labeled species with simi- 
lar  characteristics  were  obtained  with  samples  of media 
conditioned by MvlLu mink lung epithelial cells or WI-38 
human lung fibroblasts; the signal obtained with medium 
conditioned by ~E9 rat myoblasts (not shown) was not sig- 
nificantly above  a  low  background  signal  given by  fresh 
medium containing 20% FCS (see Fig. 5). The level of the 
TGF-/~ binding species in the various conditioned media was 
roughly proportional to the level of cell surface betaglycan 
in each of the cell lines surveyed as judged by the intensity 
of labeling with '2~I-TGF-/31 (Table I). 
Experiments with serum-free medium were performed in 
order to assess the cellular origin of the TGF-/~-binding spe- 
cies in the medium. Of  the cell lines with a high yield of solu- 
ble TGF-fl-binding species, only Rat-1 cells survived well in 
long-term culture under serum-free conditions.  Confluent 
monolayers of Rat-1 cells were rinsed twice with serum-free 
medium  and  incubated  for 4  h  with  serum-free medium 
to allow dissociation of serum components from the cell 
monolayer.  They  were  then  allowed to condition serum- 
free medium for 3 d.  These media had a level of TGF-/3- 
binding species that was "~65 % of  the level present in serum- 
containing media  conditioned by  parallel  cultures  of the 
same cell line, as determined by the intensity of labeling with 
~25I-TGF-/31 (not shown). These results indicated that a large 
proportion  of the  TGF-/~-binding species  in  the medium 
were  cell  products  rather  than serum  components.  Their 
lower level in serum-free conditioned medium is attributa- 
ble, at least in part, to depressed cellular activity in the ab- 
sence of serum. Since medium conditioned by 3T3-L1 fibro- 
blasts  was the richest source of TGF-/3-binding material, 
most of the  subsequent experiments  were  done with this 
medium. 
The  proteoglycan nature of the TGF-/3-binding species 
from conditioned medium and their relationship to cell sur- 
face betaglycan was further assessed by treatment with gly- 
cosaminoglycan-digesting enzymes. Treatment of the affin- 
ity-labeled soluble product from 3T3-L1  cells with either 
chondroitinase ABC which digests chondroitin sulfate chains, 
or heparitinase which digests heparan sulfate chains, led to 
a partial conversion of  the labeled material into core products 
of 120-130  kD ("~110-120 kD after subtracting the molecu- 
lar mass of one cross-linked TGF-/~ monomer) (Fig. 2 A). 
Both enzymes acting together led to a  virtually complete 
conversion of the labeled material  into  120-130-kD  core 
products (Fig. 2 A). The results shown in Fig. 2 A suggest 
that the 200-300-kD  soluble TGF-/3-binding species con- 
sisted of molecules containing either heparan sulfate or chon- 
droitin sulfate glycosaminoglycan  chains, whereas the ,~400- 
kD form appeared to be a chondroitin sulfate proteoglycan. 
Thus, these TGF-/3-binding species are proteoglycans with 
properties similar to those of cell surface betaglycan from 
3T3-L1 fibroblasts and other cell lines (7, 30). 
However,  the core components of the soluble and mem- 
brane-bound forms of betaglycan devoid of glycosaminogly- 
can chains showed significant  differences in their electropho- 
retic mobility. Membrane betaglycan yielded three distinct 
labeled core products of 120, 130, and 140 kD, respectively 
Table L Relative Levels of  Solable and Cell 
Surface Betaglycan 
Betaglycan  Cell surface 
Source*  in medium  betaglycan§ 
cpm(:  Binding sites/ 
cell ×  10  -3 
3T3-LI  mouse embryo fibroblast  12,600  120 
3T3-LI  adipocyte  15,160  120 
CCL-39 hamster tung fibroblast  5,940  20 
Rat-1  rat embryo fibroblast  2,620  18 
MvlLu mink lung epithelial  950  5 
WI-38 human lung fibmblast  240  1 
MG-63 human osteosarcoma  220  1 
rat skeletal muscle myoblast  250  <0.3U 
FCS (10% in medium)  170  - 
Calf serum (10% in medium)  80  - 
* All cell lines were grown with  10%  FCS or  10%  calf serum, except for 
L6E9 cells which were grown with 20%  FCS. 
12~I-TGF-~I cpm associated with the afffinity-labeled betaglycan band cor- 
responding to  12-ml aliquots of conditioned media. 
J TGF-8-binding sites per cell,  as determined by saturation binding assays 
and afffinity-labeling assays. 
I{ Below  the detection limit of 300 sites/cell. 
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soluble and membrane-bound 
TGF-/%binding proteoglycans. 
(A)  Affinity-labeled  anionic 
components  from 3T3-LI  fi- 
broblast  conditioned  medium 
were incubated with chondro- 
itinase ABC (ABC), hepariti- 
nase (H), both enzymes (ABC/ 
H), or buffer alone  (-).  (B) 
3T3-LI cell monolayers (Cell) 
treated  with  chondroitinase 
plus heparitinase  (+) or with 
buffer alone (-) were affinity 
labeled  with  125I-TGF-/31, ex- 
tracted  with  detergent,  and 
electrophoresed in parallel with 
affinity-labeled  secreted  pro- 
teoglycans  that  had  been  treated  with  these  enzymes  or  with  buffer  alone.  A  small  amount  of betaglycan  core  proteins  lacking 
glycosaminoglycan chains is typically observed in nondigested 3T3-L1 cells (reference 7). (C) 3T3-LI conditioned media and detergent 
extracts of 3T3-LI cells, affinity-labeled on DEAE-Sepharose,  were treated with chondroitinase  and heparitinase  followed by incubation 
with endoglycosidase F (+) or buffer alone (-). This material  was then displayed by electrophoresis  and autoradiography. 
(Fig. 2 B and reference 7), whereas soluble betaglycan yield- 
ed a broadly migrating labeled core of 120-130-kD (Fig. 2 
B), which in some experiments was poorly resolved into two 
bands. The diffuse appearance of the soluble betaglycan core 
relative to the membrane betaglycan core products was not 
an artifact of the labeling procedure performed with DEAE- 
Sepharose-bound material,  since the  detergent-solubilized 
membrane betaglycan affinity labeled on DEAE-Sepharose 
still yielded the distinct pattern of three core components af- 
ter  removal of the  glycosaminoglycan chains  (Fig.  2  C). 
Similar results were obtained with membrane and soluble 
betaglycans from Rat-1 cells (not shown). As seen in Fig. 2 
and as previously noted (5, 7), 3T3-L1 cells expressed a low 
level of membrane betaglycan cores devoid of glycosamino- 
glycan chains. 
Treatment  with  endoglycosidase  E  an  enzyme that  re- 
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Figure  3.  ~2SI-TGF-BI binding  to  3T3-LI  medium  betaglycan. 
Equilibrium binding saturation curve obtained by determining the 
amount of TGF-B1 specifically bound to soluble proteoglycan from 
3T3-LI  cells  using  50 pM  125I-TGF-B1 and  sufficient TGF-B1 to 
achieve the indicated final concentrations. Nonspecific 125I-TGF-fll 
binding  determined  in the presence of 20 nM  TGF-BI was 0.04 
fmol/ml and has been subtracted from all data points. (Inset) Scatch- 
ard plot of the same data. 
moves many types of N-linked glycan chains from glycopro- 
teins,  decreased the  apparent  molecular mass of the  core 
products from membrane-bound and soluble betaglycans by 
"~10 kD,  but did  not alter the different appearance of the 
deglycosylated core  products  from both betaglycan forms 
(Fig. 2 C). Differences were also apparent between the fully 
glycosylated  membrane-derived  and  secreted  betaglycan 
forms.  The soluble forms resolved on gels into two broad 
bands  whereas  the  membrane  form migrated  as  a  single 
broad band (see Figs.  2 B, 4,  and 6 B). 
Ligand Binding Properties of  Secreted Betaglycan 
Equilibrium binding assays performed with the DEAE-Seph- 
arose-bound fraction prepared from media conditioned for 
3 d by a confluent monolayer of 3T3-L1 fibroblasts indicated 
that the anionic fraction from these media contained a TGF- 
~/1-binding  capacity of 16 fmol/ml with a Kd of 1.9 nM, as 
determined by Scatchard analysis of the binding data (Fig. 
3). Based on these results, it is calculated that a near-conflu- 
ent (8-9  x  10  4 cells/cm  2) monolayer of 3T3-LI cells, which 
contain  "~1.2  x  1@  type III (betaglycan) TGF-/3-binding 
Figure  4.  Affinity-labeling 
competition  assay  of soluble 
betaglycan. Soluble proteogly- 
cans released by 3T3-L1 cells 
were bound to DEAE-Sepha- 
rose and affinity labeled with 
150  pM  125I-TGF-~I  in  the 
presence of the indicated con- 
centrations  of  TGF-81. (Ar- 
rows) The two major labeled 
betaglycan species whose  la- 
beling was inhibited by TGF-~I. 
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taglycan in the medium that was at least 16-19%  of the level 
of membrane-bound betaglycan. This calculation does not 
assume any losses of betaglycan that might occur during the 
chromatography steps and the binding assay.  Competition 
affinity-labeling assays (Fig. 4) indicated that half-maximal 
inhibition of soluble betaglycan labeling was obtained with 
~1 nM TGF-/31, which is in good agreement with the results 
of the equilibrium binding assays, 
Betaglycan in Serum and ExtraceUular Matrix 
The DEAE-Sepharose-bound fraction of fresh culture medi- 
um containing 10%  FBS was used as a control during the 
survey of media conditioned by cell lines described above. 
Affinity labeling of this fraction with ~25I-TGF-~I yielded a 
low but measurable amount of  labeled high molecular weight 
components. To confirm the possible relationship of these 
components to betaglycan, samples of FBS were subjected 
to DEAE-Sepharose chromatography, and the bound mate- 
rial was affinity labeled with ~25I-TGF-/31 followed by incu- 
bation with or without heparitinase and chondroitinase ABC. 
Electrophoretic analysis of these samples revealed the pres- 
ence of specific TGF-/3-binding proteoglycan(s) that yielded 
labeled core products of 120-130  kD after treatment with 
glycosaminoglycan-degrading enzymes (Fig. 5). 
Secreted proteoglycans can be deposited in extracellular 
matrices (14), and certain membrane proteoglycans can bind 
to extraceUular matrix collagen and fibronectin (19).  We 
therefore investigated whether soluble betaglycan is present 
in the extracellular matrix of 3T3-L1 cells. Cell monolayers, 
washed extensively with serum-free medium, were extracted 
with a  urea-containing buffer which  has  previously been 
used to extract extracellular matrix components including 
matrix-associated proteoglycans (1). When subjected to the 
same experimental protocol described above for the identifi- 
cation of betaglycan in serum, the extracellular matrix ex- 
tracts from 3T3-L1 cell monolayers yielded affinity-labeled 
Figure 5.  Betaglycan in FCS and 3T3-L1 fibroblast extracellular 
matrix. Highly anionic material from FCS or from the extracellular 
matrix of confluent 3T3-LI cells was bound to DEAE-Sepharose 
and affinity labeled with ~25I-TGF-/51 alone or in the presence of an 
excess of TGF-BI. After elution from the beads, the affinity-labeled 
material was incubated with chondroitinase ABC plus heparitinase 
(Enzymes +) or with buffer alone, and was then subjected to elec- 
trophoresis and autoradiography.  The material loaded per lane was 
derived from 8 ml of serum or from 6  x  106 cells. 
high molecular weight material that poorly penetrated the 
electrophoresis gels,  but whose labeling  with  '25I-TGF-B1 
was partially inhibited by the presence of an excess of TGF- 
/31.  More  importantly,  treatment  of these  affinity-labeled 
samples with heparitinase and chondroitinase ABC resulted 
in the generation of specifically labeled 120-130-kD prod- 
ucts characteristic of betaglycan (Fig. 5).  The level of be- 
taglycan detectable in extracellular matrix extracts from 3T3- 
L1 cells was ~2-5 % of that seen in the medium conditioned 
by an equivalent number of cells. 
The core products from serum-derived and extracellular 
matrix betaglycans appear in the experiments shown in Fig. 
5 as a doublet containing a diffuse major band and a sharper 
lower  molecular  weight  band.  From  examination  of the 
Coomassie blue-stained gels (not shown) it was evident that 
the lower band  is  the result of artifactual disruption and 
sharpening of the labeled band by an abundant 120-kD pro- 
tein contaminant present in the samples. This contaminant 
originated in the albumin preparation used during enzyme 
treatment of the samples. The reason for the appearance of 
this artifact only in extracellular matrix or serum-derived 
samples is that a relatively large amount of sample with a 
large amount of  albumin had to be loaded on the gels in order 
to visualize the labeled products. 
Evidence  for a Hydrophobic Membrane Anchor in 
Membrane Betaglycan but Not in Soluble Betaglycan 
The presence of a membrane anchor in cell surface betagly- 
can has been inferred from the ability of detergents but not 
chaotropic agents or glycosaminoglycan-digesting  enzymes 
to release membrane-associated betaglycan (7, 24,  30).  In 
the present studies, we determined the intrinsic ability of 
membrane-derived and soluble betaglycans to become inter- 
calated into liposomes. For this purpose, 3T3-L1 cell surface 
betaglyean was affinity labeled with J25I-TGF-/31, solubilized 
with octylglucoside, and partially purified by chromatogra- 
phy over DEAE-Sepharose.  This material was mixed with 
phosphatidylcholine in the presence of octylglucoside. The 
liposomes formed by dialysis of this mixture against buffer 
lacking detergent were separated from the unincorporated 
material by centrifugation through a  sucrose density gra- 
dient. Approximately half  of the membrane-derived betagly- 
can associated with the liposomes and was found at the top 
of the gradient (Fig. 6 B), consistent with the presence of a 
membrane anchor in this form of betaglycan. Furthermore, 
all of the membrane betaglycan remained near the bottom of 
the gradient if liposomes were disrupted with Triton X-100 
before centrifugation (Fig. 6 B). In contrast to the ability of 
membrane betaglycan to intercalate into liposomes, affinity- 
labeled soluble betaglycan did not associate with liposomes 
and remained in the bottom of the sucrose gradients (Fig. 6 
B). Disruption of liposomes with detergent before centrifu- 
gation did not alter the position of soluble betaglycan in the 
gradients. The failure of a portion of the membrane-derived 
betaglycan to bind to liposomes (Fig. 6 B) might be due to 
inefficiency  of the technique, proteolysis during the liposome 
reconstitution process, or contamination of the cell samples 
with soluble material. 
Interestingly, the membrane betaglycan core products ob- 
tained by enzyme digestion of the liposome-containing frac- 
tions from sucrose density gradients included the lowest mo- 
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line liposomes were formed in the presence of afffinity-labeled  be- 
taglycans from 3T3-LI cells or 3T3-L1 conditioned medium. Each 
liposome suspension was divided in two aliquots, one of which re- 
ceived 1% Triton X-100  to dissolve the liposomes. Each sample was 
loaded in the bottom of  a sucrose gradient. After centrifugation, the 
gradients were fractioned from top (Fraction 1) to bottom. The 
macromolecular material from these fractions and the pellets from 
each gradient were displayed by electrophoresis and autoradiogra- 
phy. One-third of each fraction from the sample corresponding to 
cell material without detergent was devoted to an experiment simi- 
lar to the one described in Fig. 7. B shows the relevant portion of 
the resulting autoradiograms. A shows the distribution of the iipo- 
some marker, [3H] dipalmitoyl phosphatidycholine, as determined 
by counting small aliquots from the top set of gradient fractions 
shown in B. 
determined by subjecting them to hydrophobic chromatog- 
raphy  on  octyl-Sepharose and  elution  with  a  gradient of 
octylglucoside. Although all betaglycan forms bound to oc- 
tyl-Sepharose,  the  interaction of soluble  betaglycan  with 
octyl-Sepharose was weak. This form of betaglycan began to 
elute at a concentration of octylglucoside (,x,10 mM) well be- 
low the critical micelle concentration (23 mM) of this deter- 
gent (Fig. 8). Electrophoretic analysis of the peak fractions 
showed that the split appearance of the soluble betaglycan 
peak in Fig. 8 was due to elution of nonspecifically labeled 
high molecular weight material (see Fig. 1) with the late frac- 
tions of the betaglycan peak. Membrane-derived betaglycan 
had  stronger affinity for octyl-Sepharose, and eluted with 
,'o35 mM octylglucoside. Taken together, these results pro- 
vide strong evidence for the presence of  a hydrophobic mem- 
brane anchor in membrane betaglycan that is absent in the 
soluble betaglycan. 
Discussion 
The finding of soluble forms of betaglycan (formerly, the 
type III  TGF-/3  receptor) coexisting with  the  membrane- 
bound forms provides new insight into the structural proper- 
ties  and  potential biological role of these TGF-/3-binding 
proteoglycans. The soluble proteoglycans identified in this 
report have the general structural and functional properties 
that  characterize membrane-bound betaglycan except that 
the soluble forms lack a membrane anchor. Thus, betaglycans 
are defined as  membrane bound or soluble proteoglycans 
with a core protein of 100-120 kD that contains a high affin- 
ity binding site for TGF-/3, and carries ~10 kD of N-linked 
glycan chains and between 100 and 300 kD of  heparan sulfate 
and/or chondroitin sulfate glycosaminoglycan chains, as de- 
termined by SDS-PAGE. 
The membrane and soluble forms of betaglycan differ in 
their hydrophobic properties and their ability to associate 
with liposomes. Previous studies have shown that anchorage 
of betaglycan to the cell surface is via the core protein (4, 
7, 30). The absence of a hydrophobic membrane anchor in 
soluble betaglycan does not increase the mobility of the core 
protein on electrophoresis gels when compared to the mem- 
brane betaglycan core protein; the apparent molecular weight 
of the secreted betaglycan core is not smaller than the small- 
lecular mass (120-kD) labeled core species (Fig. 7).  Since 
the apparent molecular weight of this core component was 
not significantly larger than the molecular weight of the core 
products derived from soluble betaglycan (see Fig. 2), these 
results suggest that the betaglycan membrane anchor and, 
if present, the cytoplasmic domain have a  relatively small 
mass. 
In a complementary set of experiments, the hydrophobic 
character of soluble and membrane-derived betaglycans was 
Figure 7. Core proteins from liposome-associated betaglycan. After 
liposome intercalation and fractionation on a sucrose density gra- 
dient as described in Fig. 6, affinity-labeled  cell surface bctaglycan 
from 3T3-LI cells was treated with chondroitinase ABC plus hep- 
aritinase, and subjected to electrophoresis and autoradiography to 
display the core proteins of the betaglycan in each fraction of the 
gradient. 
The Journal of Cell Biology,  Volume 109, 1989  3142 12  80 
,  9 
0 
X 
E  6 
d 
3 
Membrane  Betaglycan~l 
. Secreted 
0  10  20  30 
y- 
60  K 
40  "~ 
2o 
0 
40 
Fraction number 
Figure  8.  Octyl-Sepharose 
chromatography  of membrane- 
derived and soluble betagly- 
cans. DEAE-Sepharose frac- 
tions containing  affinity-labeled 
betaglycans  from 3T3-LI cells 
and from conditioned medium 
were chromatograpbed  over an 
octyl-Sepharose column elut- 
ed with a linear gradient ofoc- 
tylglucoside. The  125I radio- 
activity in the resulting frac- 
tions was then determined. 
est membrane betaglycan core that associates with liposomes. 
This result suggests that the betaglycan membrane anchor and, 
if present, the cytoplasmic domain might be small. We have 
been unable to release membrane-bound betaglycan by hy- 
drolysis with the phosphoinositol-specific phospholipase C 
(21) that cleaves glycosyl-phosphatidylinositol  anchors pres- 
ent in certain membrane proteins (data not shown). Attempts 
to release membrane betaglycan included treatment of cells 
with this phospholipase  either before or  after affinity-la- 
beling cells with TGF-B, with or without previous enzymatic 
removal of glycosaminoglycans, or followed by rinsing cells 
with a 1 M urea solution. These results suggest the presence 
of a polypeptide membrane anchor in betaglycan, and are 
consistent with the domain structure model proposed on the 
basis of tryptic fragmentation analysis of membrane betagly- 
can (7). 
Additional differences between the membrane and soluble 
forms of betaglycan from 3T3-L1 cells are suggested by their 
pattern of migration on electrophoresis gels. Membrane be- 
taglycan migrates on electrophoresis gels as a broad band of 
250-350  kD  whereas  soluble betaglycan migrates as two 
broad bands between the 200-kD mark and the top of the 
gels. These differences may be attributable to differences in 
the number or type of glycosaminoglycan  chains attached to 
each proteoglycan. The core proteins from membrane and 
soluble betaglycans also show differences: membrane be- 
taglycan core proteins resolve as three distinct species of 
100, 110, and 120 kD (after subtracting the mass of N-linked 
glycans and cross-linked TGF-B monomer) whereas solu- 
ble betaglycan core protein(s) migrate as a broad 100-110- 
kD band. 
Do cells constitutively release a portion of the membrane 
betaglycan that they synthesize? Soluble betaglycan is pro- 
duced by several  types of fibroblasts, lung epithelial cells, 
and adipocytes derived from five different mammalian spe- 
cies; it is produced by proliferating cells as well as quiescent, 
terminally differentiated adipocytes; and,  the level  of be- 
taglycan in the medium of all cell lines examined is propor- 
tional to the level of membrane-bound betaglycan. Thus, the 
available evidence is, in part, compatible with the hypothesis 
that soluble betaglycan might be constitutively released by a 
hydrolytic event that cleaves the hydrophobic anchor of mem- 
brane betaglycan. However,  the differences in electropho- 
retic mobility observed between membrane betaglycan and 
soluble betaglycan tend to support the alternative hypothesis 
that the various forms of betaglycan are synthesized or post- 
translationally modified as separate products. Precedent for 
this possibility exists. For example, alternative mRNA splic- 
ing events lead to the coexpression of membrane-bound and 
secreted forms of the intercellular recognition molecules, 
neutral adhesion molecular N-CAM (12),  major histocom- 
patibility complex Qa-2 antigen (33),  and lymphocyte cell 
surface molecule CD8 (10). Clearly, more work is needed to 
determine the origin of soluble betaglycan and the potential 
regulation of its expression. 
Betaglycan in serum added to cell cultures represents only 
a small fraction (1-6%, Table I) of the total soluble betagly- 
can in the 3T3-L1, Rat-I, and CCL-39 conditioned media. 
The results of control experiments described above clearly 
indicate that most of the betaglycan in conditioned media is 
produced by the cells in culture.  On the other hand, the 
finding of soluble betaglycan in fetal serum is significant be- 
cause it indicates that release of betaglycan is not an event 
restricted to cells in culture. It will be of interest to determine 
if betaglycan is present in circulating plasma, whether its 
presence in serum is due to events that occur during the 
blood clotting process, or whether its role in circulation is 
related to that of ot2-macroglobulin which can also bind 
TGF-# (34). 
The ability of betaglycan to bind TGF-/3, its proteoglycan 
structure, and its polymorphic nature suggests that betagly- 
can might be a multifunctional molecule. Its potential roles 
include mediation of "I'GF-B action, mediation of cell adhe- 
sion, and a role as a pericellular TGF-~ chelator. With re- 
gards to the former possibility, genetic evidence (2)  and 
pharmacological evidence (27) indicate that the type I TGF-B 
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to TGF-fl, and that it can act in the absence of betaglycan ex- 
pression. This evidence, the structural features of betaglycan 
revealed by the present studies, and release of betaglycan into 
the medium do not support the initial proposal (6, 24) of a 
direct role  for this molecule in transmembrane  signaling. 
More attractive is the suggested possibility that membrane 
betaglycan might participate in cell-to-cell or cell-to-extra- 
cellular matrix adhesion (7). This potential role of betagly- 
can has a precedent in other well characterized membrane 
proteoglycans, including syndecan from mammary epithelial 
cells (19) and the CD44/Hermes lymphocyte homing recep- 
tor (11, 32). Interestingly,  syndecan is also found in soluble 
and membrane-bound forms (35). 
Betaglycans might be involved in TGF-B action by inter- 
vening in ligand presentation  to the other TGF-fl receptor 
types, or by serving as pericellular  reservoirs of bioactive 
TGF-fl (2). A role for betaglycan as a pericellular reservoir 
of TGF-B becomes particularly plausible with our finding of 
soluble betaglycan in the medium and the extracellular ma- 
trix of cultured fibroblasts. Interstitial collagens, fibronectin, 
and other extracellular matrix components have glycosamino- 
glycan-binding domains that allow the assembly of soluble 
proteoglycans into extracellular matrices (14). Similar inter- 
actions might occur with soluble betaglycan. Since the gly- 
cosaminoglycan chains are not required for expression, mem- 
brane anchorage  or TGF-fl-binding  activity of betaglycan 
(4), they may be available for interaction with extracellular 
matrix components. Only low levels of betaglycan, however, 
are detectable in the extracellular  matrix  of 3T3-L1  cells. 
This could be due to competition between betaglycan and the 
abundant  3T3-LI  secreted proteoglycans,  biglycan (PG I), 
and decorin (PG II) (1, 9,  19, 20), for binding to a relatively 
poorly structured extracellular matrix. In vivo, the accumu- 
lation of soluble betaglycan in extracellular matrices might 
be quantitatively more important than  in vitro.  It is worth 
noting in this regard that TGF-fl is present in abundance in 
tissues that have a high content of extracellular matrix, such 
as bone (31). Immunohistochemical  evidence indicates that 
TGF-fl, which itself is a major regulator of extracellular ma- 
trix deposition (17, 28) and cell adhesion  (18),  indeed ac- 
cumulates in extracellular matrices of bone and other tissues 
(3, 15, 31). It will be of interest to determine how betaglycan 
as a component of extracellular matrices may participate in 
such  important  functions  as  localized  retention,  delivery, 
receptor presentation,  and clearance of activated TGF-fl. 
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